Recent Updates on CDK4/6 Inhibitors for HR-Positive, HER2-Negative Metastatic Breast Cancer

home / insights / recent-updates-on-cdk46-inhibitors-for-hr-positive-her2-negative-metastatic-breast-cancer

Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.

Expert on breast cancer

EP. 1: Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
June 15th 2022
Expert on breast cancer

EP. 2: HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
June 15th 2022
Expert on breast cancer

EP. 3: Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
June 22nd 2022
Expert on breast cancer

EP. 4: PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
June 22nd 2022
Expert on breast cancer

EP. 5: MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
June 29th 2022
Expert on breast cancer

EP. 6: MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
June 29th 2022
Expert on breast cancer

EP. 7: HR+/HER2- Metastatic Breast Cancer: Selecting From Approved CDK4/6 Inhibitors

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
July 6th 2022
Expert on breast cancer

EP. 8: Importance of Molecular Testing in HR+/HER2- Metastatic Breast Cancer

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
July 6th 2022
Expert on breast cancer

EP. 9: HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
July 13th 2022
Expert on breast cancer

EP. 10: Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
July 13th 2022
Expert on breast cancer

EP. 11: Overcoming Resistance in HR+/HER2- mBC: Novel ADC and SARM Therapy

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
July 20th 2022
Expert on breast cancer

EP. 12: Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
July 20th 2022
Expert on breast cancer

EP. 13: Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
July 27th 2022
Expert on breast cancer

EP. 14: HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial Readouts

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD
July 27th 2022